- Home
- ARMP vs TIMB Comparison
ARMP vs TIMB Comparison
Compare ARMP & TIMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- TIMB
- Stock Information
- Founded
- ARMP N/A
- TIMB 1998
- Country
- ARMP United States
- TIMB Brazil
- Employees
- ARMP N/A
- TIMB N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- TIMB Telecommunications Equipment
- Sector
- ARMP Health Care
- TIMB Telecommunications
- Exchange
- ARMP Nasdaq
- TIMB Nasdaq
- Market Cap
- ARMP 92.4M
- TIMB 94.1M
- IPO Year
- ARMP N/A
- TIMB 1998
- Fundamental
- Price
- ARMP $2.61
- TIMB $20.94
- Analyst Decision
- ARMP Strong Buy
- TIMB Hold
- Analyst Count
- ARMP 1
- TIMB 4
- Target Price
- ARMP $9.00
- TIMB $20.17
- AVG Volume (30 Days)
- ARMP 9.3K
- TIMB 384.4K
- Earning Date
- ARMP 08-12-2025
- TIMB 07-30-2025
- Dividend Yield
- ARMP N/A
- TIMB 6.39%
- EPS Growth
- ARMP N/A
- TIMB 16.41
- EPS
- ARMP N/A
- TIMB 0.27
- Revenue
- ARMP $6,868,000.00
- TIMB $4,779,664,328.00
- Revenue This Year
- ARMP $8.43
- TIMB $8.22
- Revenue Next Year
- ARMP N/A
- TIMB $5.10
- P/E Ratio
- ARMP N/A
- TIMB $14.90
- Revenue Growth
- ARMP 84.67
- TIMB 5.32
- 52 Week Low
- ARMP $0.90
- TIMB $11.32
- 52 Week High
- ARMP $2.96
- TIMB $21.04
- Technical
- Relative Strength Index (RSI)
- ARMP 58.67
- TIMB 66.41
- Support Level
- ARMP $2.43
- TIMB $20.28
- Resistance Level
- ARMP $2.72
- TIMB $20.60
- Average True Range (ATR)
- ARMP 0.18
- TIMB 0.32
- MACD
- ARMP -0.01
- TIMB 0.05
- Stochastic Oscillator
- ARMP 70.08
- TIMB 91.89
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About TIMB TIM S.A. (Each representing 5)
TIM, which is 67%-owned by Telecom Italia, is the third largest wireless carrier in Brazil, with 62 million subscribers, equal to about 24% of the market. The firm also owns 49% of I-Systems, an infrastructure partnership that is expanding its network footprint across Brazil. I-Systems can provide broadband service to about 9 million locations, equal to 10%-15% of the country. TIM leases capacity on the venture's network to serve retail broadband customers under the UltraFibra brand. TIM also resells fiber network access from other providers, including Oi's former infrastructure business V.tal. In total, TIM claims it can offer fixed broadband service to about 16 million locations.